Investors pour $8M into Raleigh medical device startup; its drug delivery tech traces roots to UNC-CH wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial
February 11, 2021 GMT
Advanced Chemotherapy Technologies ACT-IOP-003 iontophoresis chemotherapy delivery system (Photo: Business Wire)
RALEIGH, N.C. (BUSINESS WIRE) Feb 10, 2021
Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a Series A investment of $2.5 million with Spectrum Financial. This investment is in addition to the previously announced Series A investment of $5.5 million lead by Khosla Venture. The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local chemotherapy system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.
E-Mail
IMAGE: UNC Lineberger Comprehensive Cancer Center s Jonathan S. Serody, MD, and colleagues report that adding a small molecule to a chimeric antigen receptor-T (CAR-T) cell therapy can help immune system T. view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, NC Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more immune cells into battle at the tumor site. The findings are published in the